Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Short Interest Update

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) was the target of a large decrease in short interest in July. As of July 31st, there was short interest totaling 262,477 shares, a decrease of 51.7% from the July 15th total of 542,999 shares. Based on an average daily volume of 793,416 shares, the days-to-cover ratio is presently 0.3 days. Approximately 3.0% of the shares of the company are short sold.

Institutional Investors Weigh In On Tvardi Therapeutics

Several hedge funds have recently added to or reduced their stakes in TVRD. BlackRock Inc. purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter valued at about $181,000. GSA Capital Partners LLP acquired a new position in shares of Tvardi Therapeutics in the 2nd quarter valued at about $34,000. XTX Topco Ltd acquired a new position in shares of Tvardi Therapeutics in the 4th quarter valued at about $55,000. Quadrature Capital Ltd purchased a new stake in shares of Tvardi Therapeutics in the fourth quarter worth about $90,000. Finally, Russell Investments Group Ltd. boosted its stake in shares of Tvardi Therapeutics by 1,351.5% in the fourth quarter. Russell Investments Group Ltd. now owns 15,966 shares of the company’s stock worth $69,000 after buying an additional 14,866 shares during the last quarter. 44.66% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Raymond James Financial raised shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target for the company in a report on Wednesday, July 8th. BTIG Research cut their target price on Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. UBS Group raised Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price on the stock in a research report on Wednesday, July 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Wednesday, July 8th. Finally, Piper Sandler raised Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price target for the company in a research report on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Tvardi Therapeutics Stock Performance

TVRD opened at $1.90 on Monday. Tvardi Therapeutics has a 12-month low of $1.50 and a 12-month high of $43.65. The firm has a 50 day moving average of $2.49 and a two-hundred day moving average of $3.18. The firm has a market capitalization of $17.82 million, a PE ratio of -0.68 and a beta of 0.39.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04). As a group, analysts predict that Tvardi Therapeutics will post -2.32 EPS for the current fiscal year.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.